Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02802566

BMI-based Vitamins in Obese Pregnant Women

The purpose of this study is to devise and pilot a BMI-based prenatal vitamin for obese pregnant women. Currently, all pregnant women, regardless of body mass index, take the same prenatal vitamin. The investigators have found that obese pregnant women have higher levels of inflammation and oxidative stress, and a concomitant depletion of specific antioxidant micronutrients. The investigators have also found, in an animal model, that decreasing inflammation and oxidative stress during obese pregnancy was associated with improved offspring outcomes. Here the investigators aim to understand whether a BMI-based prenatal vitamin is effective in decreasing markers of inflammation and oxidative stress by raising concentrations of antioxidant micronutrients and in pregnancies complicated by obesity.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Loading trial locations.

About this study

The investigators' central hypothesis is that pregnancy in obese women creates an oxidant/anti-oxidant imbalance, which adversely impacts maternal health and neonatal outcome. The investigators hypothesize that restoring oxidant/anti-oxidant balance with a body mass index (BMI) based prenatal micronutrient supplement will decrease oxidative stress. The investigators aim to devise a prenatal vitamin supplement based on maternal BMI to increase serum levels of antioxidant vitamins in obese pregnancy, to assess how the BMI-based prenatal vitamin supplementation impacts markers of oxidative stress and inflammation in obese pregnant women and to evaluate the effectiveness of this vitamin formulation in reducing oxidative stress and inflammation and improving growth trajectories in infants born to obese women.

The investigators will conduct a double-blind randomized-controlled study. Two groups of women will be randomized independently. 1) Obese women (BMI>30) planning pregnancy through the through advertising and mailings (N=50) and 2) Pregnant women who are early in pregnancy (<13 weeks) will be approached at their first prenatal visit at the BWH and BIDMC obstetric practices (N=120).

Women will be prescreened and approached by study staff if they qualify. After informed consent is obtained, patients will be randomized to either control or intervention group by computer-generated permuted block randomization. All subjects will be given a standard prenatal vitamin provided by the study and in addition, the control group will be given a placebo and the Intervention group will be given a supplement with vitamin C, E, B6 and folate.

The outcomes are maternal systemic markers inflammation and oxidative stress and micronutrients. At the time points mentioned above, the following laboratory assays will be conducted in maternal blood or urine: C reactive protein, vitamins C, E, B6, folate 8-iso-PGF2a and 8-OHdG. The secondary outcomes are cord blood markers of inflammation and oxidative stress, breastfeeding outcomes, and the following infant outcomes over the first year: neurodevelopmental outcome, growth trajectories and adiposity, systemic markers of inflammation and oxidative stress.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pre-pregnancy weight or early first trimester weight (BMI > or equal to 30 kg/m2)
  • Women can be either planning pregnancy (who are trying to conceive or will be trying to conceive in the coming 6 months) or <14 weeks pregnant

Exclusion criteria

  • More than two first trimester pregnancy losses
  • History of delivering an infant with a major congenital anomaly
  • Pre-existing diabetes
  • Autoimmune disease such as lupus
  • Chronic inflammatory condition such as rheumatoid arthritis
  • Uncontrolled stage two or three hypertension at baseline (systolic>160 or diastolic>100 mmHg)
  • On anticoagulant therapy
  • History of cigarette smoking within the past 12 months
  • Lactose intolerant
  • Vegan
  • Unwilling to stop taking their current supplements

Treatment and study plan

BMI-based prenatal vitamin

Dietary Supplement

The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.

Standard prenatal vitamin

Dietary Supplement

Standard prenatal vitamin

Primary outcomes

  1. Maternal systemic marker of inflammation

    Time frame: 35-40 weeks of pregnancy

    Serum C Reactive Protein

  2. Maternal systemic marker of oxidative stress

    Time frame: 35-40 weeks of pregnancy

    Urinary 8-Oh-dG

Secondary outcomes

  1. Maternal antioxidant vitamins

    Time frame: 35-40 weeks of pregnancy

    Plasma Vitamin C

  2. Maternal antioxidant vitamins

    Time frame: 35-40 weeks of pregnancy

    Serum Vitamin B6

  3. Maternal antioxidant vitamins

    Time frame: 35-40 weeks of pregnancy

    Serum Vitamin E

  4. Maternal antioxidant vitamins

    Time frame: 35-40 weeks of pregnancy

    Serum and Red Blood Cell folate

  5. Cord blood marker of inflammation

    Time frame: Delivery

    Serum C Reactive Protein

  6. Cord blood markers of oxidative stress

    Time frame: Delivery

    8-epi-PGF2 alpha

  7. Breastfeeding intensity

    Time frame: two, six and twelve months postpartum

    Complete questionnaire on infant feeding

  8. Infant weight

    Time frame: birth, 6 months and one year

    Measure infant weight (kg)

  9. Infant length

    Time frame: birth, six months and one year

    length (cm) measured using a length board

  10. Infant head circumference

    Time frame: birth, six months and one year

    head circumference (cm) will be measured using tape measure technique

  11. Infant adiposity

    Time frame: birth, six months and one year

    adiposity by peapod measurement at birth and by skin fold thickness at birth, six months and one year

  12. Infant marker of inflammation

    Time frame: 1 year

    Serum C Reactive Protein

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Beth Israel Deaconess Medical Center

Registry information

Official study title

BMI-Based Prenatal Vitamins to Ameliorate Oxidative Stress in Obese Pregnancy

Important dates

Study start
2014
Primary completion
2017
Study completion
2025
First posted
Jun 16, 2016
Registry last updated
Dec 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.